Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant…
CB Insights named BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, to its fifth-annual Digital Health 50 showcasing the 50 most promising private digital health companies of 2023. The 50 winners, representing eight countries across the globe, were selected from…
Thousands of ambulatory healthcare professionals from across the US traveled to Orlando last week to gather insights on navigating the ever-changing healthcare landscape, including how to leverage artificial intelligence (AI) to reduce provider burnout and maximize outcomes. Held Nov. 29…
–Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by…
Magnetic sensor specialist startup Neuranics has announced that it will launch a magnetic sensor development kit that will record the magnetic activity of the heart and wirelessly transfer this over Bluetooth for live 24/7 recording and analysis on a smartphone,…
AOP Orphan Pharmaceuticals GmbH (AOP Health) has announced the launch of Ropeginterferon alfa-2b in patients with low-risk polycythemia vera (PV). We presented the results of an analysis evaluating the impact of individually optimized dosing regimens on therapeutic efficacy. 1These new data demonstrate…
Mary Kay Inc. is the world’s leading direct-selling skin care and color cosmetics brand1 . The company and its sponsored foundations, including the Mary Kay Ash Foundation in the United States, continue to fund various research programs and projects, provide grants to world-renowned scientists, and promote clinical trials.…
ReNAgade Therapeutics, the company unlocking the limitless potential of RNA medicines, appoints Paul Perrault to its board of directors, effective December 5, 2023. I announced what I had done. Mr. Perrault most recently served as Chief Executive Officer of CSL and has…
Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates…
Registration as an organ and tissue donor is a crucial component to Donor Alliance’s mission of saving and healing lives in the region. In Colorado, nearly all organ and tissue donor registrations come through driver license offices. To recognize this important…